Monthly Archives: February 2019

Malnutrition is highly prevalent in patients with inflammatory bowel disease (IBD). This preliminary study examined the effect of a nutrition support formula on blood nutrient parameters and explored effects on circulating blood cell counts and inflamm… Continue reading →

Pediatric Crohn’s disease poses challenges due to longer cumulative duration of disease and its effect on patient growth. A “top-down” approach, with early introduction of biologics, is common in pediatrics. Anti-TNF agents are commonly used, but… Continue reading →

Indigo naturalis (IN) is a traditional Chinese herbal medicine reported to be effective for inducing remission in ulcerative colitis (UC). We conducted a retrospective observational study to investigate the efficacy and safety of IN for inducing and ma… Continue reading →

Monitoring ustekinumab (UST) concentrations and antibodies-to ustekinumab (ATU) during IBD treatment may allow more informed decisions in assessing exposure/response and appropriate dosing. To aid in interpreting results in the context of Janssen’s p… Continue reading →

Therapeutic drug monitoring methods are lacking for methotrexate (MTX), an immunomodulator used in Inflammatory Bowel Disease (IBD) treatment, alone or in conjunction with infliximab (IFX). Although studies demonstrate a lack of relationship between MT… Continue reading →

Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitorin… Continue reading →

Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitorin… Continue reading →

Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa. Infliximab has long been a standard therapy for moderate to severe UC. IV followed by oral cyclosporine (CsA) has demonstrated similar safety and efficacy to infliximab fo… Continue reading →

Infliximab (IFX) is effective for treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD). Therapeutic drug monitoring (TDM) performed during IFX maintenance treatment with a target trough level of 3-7 ug/mL has been shown to improve clinical o… Continue reading →

Although clinical efficacy of combination therapy with infliximab (IFX) and thiopurine has been demonstrated in Crohn’s disease (CD), it remains uncertain when to add thiopurine in CD patients treated with IFX. The present study aimed to clarify appr… Continue reading →